WIL Research Partners with Three S Japan
News May 24, 2013
WIL Research is partnering with Three S Japan, a company that provides support services in these industries, to represent its full portfolio of global safety assessment services in Japan.
WIL Research offers a blend of technical and regulatory expertise in discovery support, product safety toxicological research, metabolism, bioanalytical chemistry, analytical chemistry and formulation services.
They chose the Japan-based company to represent these services on the basis of its extensive network of clients, leadership experience with both pharmaceutical and chemical industry safety assessment, and its commitment to providing tailored, local client service.
“Three S Japan has a strong reputation serving the country’s pharmaceutical industry with high quality regulatory services underpinned by exceptional client focus,” said David Spaight, Chairman and CEO of WIL Research.
Spaight continued, “Through this partnership, clients will benefit from direct access to staff that can harness the full portfolio of WIL Research’s global services.”
CEO and President of Three S Japan, Koichi Hagita said, “WIL Research’s excellent reputation and our long-term client relationships and regulatory experience in the Japanese market will boost both our companies’ potential for growth.”
Three S Japan has operational centers in Tokyo and Osaka for pharmaceutical regulatory registration services.
The company provides toxicological support from pre-clinical to clinical development, and is experienced in the preparation, translation, and quality control checks of submission documents for New Drug Applications and Investigational New Drug applications.
Three S Japan also offers personalized consulting tailored to clients’ needs.
WIL Research was recently one of the winners of the CRO Leadership Award for Quality, awarded annually to leaders in quality, productivity, regulatory, accessibility, and reliability.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.